Regeneron Pharmaceuticals Inc. (REGN)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Low level of difficulty

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

		Sep 30, 2019		Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Accounts payable
	Accrued expenses and other current liabilities
	Finance lease liabilities, current portion
	Deferred revenue from Sanofi
	Deferred revenue, other
	Current liabilities
	Finance lease liabilities, excluding current portion
	Deferred revenue from Sanofi
	Deferred revenue, other
	Convertible senior notes
	Other noncurrent liabilities
	Noncurrent liabilities
	Total liabilities
	Preferred Stock, $.01 par value; issued and outstanding - none
	Class A Stock, convertible, $.001 par value
	Common Stock, $.001 par value
	Additional paid-in capital
	Retained earnings (accumulated deficit)
	Accumulated other comprehensive income (loss)
	Treasury Stock, at cost
	Stockholders’ equity
	Total liabilities and stockholders’ equity

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Regeneron Pharmaceuticals Inc.’s current liabilities as a percentage of total liabilities and stockholders’ equity increased from Q1 2019 to Q2 2019 but then slightly declined from Q2 2019 to Q3 2019.
Noncurrent liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Regeneron Pharmaceuticals Inc.’s noncurrent liabilities as a percentage of total liabilities and stockholders’ equity declined from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Regeneron Pharmaceuticals Inc.’s total liabilities as a percentage of total liabilities and stockholders’ equity declined from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Regeneron Pharmaceuticals Inc.’s stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

	Regeneron Pharmaceuticals Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

Regeneron Pharmaceuticals Inc. (REGN)

Common-Size Balance Sheet: Liabilities and Stockholders’ EquityQuarterly Data

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data